Literature DB >> 8286202

Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia.

J Cuzick1, G Terry, L Ho, T Hollingworth, M Anderson.   

Abstract

Human papillomavirus (HPV) typing and quantitation by polymerase chain reaction was performed on exfoliated cells from 133 women referred for colposcopy because of an abnormal smear. High levels of HPV 16 correctly predicted cervical intraepithelial neoplasia (CIN) grade II-III in 93% of its occurrences, but only 59% of cases of CIN III were associated with high levels of this type. Eighty-four per cent of CIN III lesions contained high levels of at least one of HPV types 16, 18, 31, 33 and 35, but the other types were less specific for CIN III than HPV 16. Overall HPV testing compared favourably with cytology for predicting high-grade CIN lesions, but it would appear that some combination of the two modalities will produce better performance than either alone. In particular, HPV testing appears to be helpful in determining which women with mildly abnormal smears have high-grade underlying lesions in need of immediate referral for colposcopy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8286202      PMCID: PMC1968760          DOI: 10.1038/bjc.1994.28

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  A comparison of the Papanicolaou smear and the cervigram: sensitivity, specificity, and cost analysis.

Authors:  K Tawa; A Forsythe; J K Cove; A Saltz; H W Peters; W G Watring
Journal:  Obstet Gynecol       Date:  1988-02       Impact factor: 7.661

2.  Genome organization and nucleotide sequence of human papillomavirus type 33, which is associated with cervical cancer.

Authors:  S T Cole; R E Streeck
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes.

Authors:  E Lăără; N E Day; M Hakama
Journal:  Lancet       Date:  1987-05-30       Impact factor: 79.321

4.  Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products.

Authors:  S T Cole; O Danos
Journal:  J Mol Biol       Date:  1987-02-20       Impact factor: 5.469

5.  A new type of papillomavirus associated with cancer of the uterine cervix.

Authors:  A T Lorincz; A P Quinn; W D Lancaster; G F Temple
Journal:  Virology       Date:  1987-07       Impact factor: 3.616

6.  The nucleotide sequence and genome organization of human papilloma virus type 11.

Authors:  K Dartmann; E Schwarz; L Gissmann; H zur Hausen
Journal:  Virology       Date:  1986-05       Impact factor: 3.616

7.  HPV 16 DNA in normal and malignant cervical epithelium: implications for the aetiology and behaviour of cervical neoplasia.

Authors:  C A Meanwell; M F Cox; G Blackledge; N J Maitland
Journal:  Lancet       Date:  1987-03-28       Impact factor: 79.321

8.  Human papillomavirus type 16 DNA sequence.

Authors:  K Seedorf; G Krämmer; M Dürst; S Suhai; W G Röwekamp
Journal:  Virology       Date:  1985-08       Impact factor: 3.616

9.  Cervicography: a new method for cervical cancer detection.

Authors:  A Stafl
Journal:  Am J Obstet Gynecol       Date:  1981-04-01       Impact factor: 8.661

10.  Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report.

Authors:  P J Bavin; J A Giles; A Deery; J Crow; P D Griffiths; V C Emery; P G Walker
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

View more
  36 in total

1.  Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay.

Authors:  I Nindl; B Lotz; R Kühne-Heid; U Endisch; A Schneider
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

2.  The role of human leucocyte antigen genes in the development of malignant disease.

Authors:  W M Howell; D B Jones
Journal:  Clin Mol Pathol       Date:  1995-12

3.  Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA.

Authors:  M Zerbini; S Venturoli; M Cricca; G Gallinella; P De Simone; S Costa; D Santini; M Musiani
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

4.  Human papillomaviruses and cervical screening.

Authors:  I J Etherington; M I Shafi
Journal:  Genitourin Med       Date:  1996-06

5.  Cervical cytology and colposcopy in clinics for sexually transmitted diseases--when are they appropriate?

Authors:  J D Wilson
Journal:  Genitourin Med       Date:  1996-12

Review 6.  Aetiology, pathogenesis, and pathology of cervical neoplasia.

Authors:  M J Arends; C H Buckley; M Wells
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

Review 7.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

8.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

9.  Study of viral integration of HPV-16 in young patients with LSIL.

Authors:  G Gallo; M Bibbo; L Bagella; A Zamparelli; F Sanseverino; M R Giovagnoli; A Vecchione; A Giordano
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

10.  Low false-negative rate of PCR analysis for detecting human papillomavirus-related cervical lesions.

Authors:  P Zazove; B D Reed; L Gregoire; A Ferenczy; D W Gorenflo; W D Lancaster
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.